Nava Therapeutics
PrivateLast Round
Series B
Aug 1, 2026
Total Funding Raised
$89M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nava Therapeutics is a biotechnology company developing a proprietary lipid nanoparticle (LNP) platform designed to deliver RNA-based genetic medicines to tissues beyond the liver.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nava Therapeutics Comparables
Compare Nava Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ai3Bio | 81% | |
| Aera Therapeutics | 73% | |
| CREATE Medicines | 73% |
Nava Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 1, 2026 |
Key People
Founding team and executive leadership
Nava Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Seed |
| RA Capital Management | Series A, Seed |
| GV | Series A, Seed |
| Readout Capital | Series A, Seed |
| Versant Ventures | Series A, Seed |
| Alexandria Venture Investments | Series A, Seed |
| F-Prime Capital | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 202% MoM, reaching 23.3K.
- Aug 1, 2026
Completed Series B funding round.
Recent news
Latest coverage and updates
- receives_financingJul 15, 2026
Navatx receives financing of $89M.
Nava Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nava Therapeutics's valuation, stock price, and market status.
Is Nava Therapeutics a public or private company?
Nava Therapeutics is a private company.
What is the current stock price of Nava Therapeutics?
Nava Therapeutics is a private company with no public stock price. Caplight tracks Nava Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Nava Therapeutics worth (valuation)?
Valuation information for Nava Therapeutics is not publicly available.
Can I buy Nava Therapeutics stock?
Nava Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nava Therapeutics's last funding round?
Nava Therapeutics's most recent funding round was Series B on August 1, 2026.
Who are the main investors in Nava Therapeutics?
Key investors in Nava Therapeutics include Andreessen Horowitz, RA Capital Management, GV, Readout Capital, Versant Ventures.
Will Nava Therapeutics IPO soon?
No public IPO plans have been announced for Nava Therapeutics.
How can I track Nava Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nava Therapeutics's secondary market activity and sign up for updates.